These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15344842)

  • 1. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase.
    Fujino H; Nakai D; Nakagomi R; Saito M; Tokui T; Kojima J
    Arzneimittelforschung; 2004; 54(7):382-8. PubMed ID: 15344842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interaction between pitavastatin and various drugs via OATP1B1.
    Hirano M; Maeda K; Shitara Y; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1229-36. PubMed ID: 16595711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.
    Hirano M; Maeda K; Shitara Y; Sugiyama Y
    J Pharmacol Exp Ther; 2004 Oct; 311(1):139-46. PubMed ID: 15159445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase.
    Fujino H; Saito T; Ogawa S; Kojima J
    J Pharm Pharmacol; 2005 Oct; 57(10):1305-11. PubMed ID: 16259759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction and Quantification of Hepatic Transporter-Mediated Uptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modeling.
    Mitra P; Weinheimer S; Michalewicz M; Taub ME
    Drug Metab Dispos; 2018 Jul; 46(7):953-963. PubMed ID: 29666154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization.
    Fujino H; Yamada I; Shimada S; Yoneda M; Kojima J
    Xenobiotica; 2003 Jan; 33(1):27-41. PubMed ID: 12519692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-incubation with cyclosporine A potentiates its inhibitory effects on pitavastatin uptake mediated by recombinantly expressed cynomolgus monkey hepatic organic anion transporting polypeptide.
    Takahashi T; Ohtsuka T; Uno Y; Utoh M; Yamazaki H; Kume T
    Biopharm Drug Dispos; 2016 Nov; 37(8):479-490. PubMed ID: 27603548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans.
    Fujino H; Yamada I; Shimada S; Nagao T; Yoneda M
    Arzneimittelforschung; 2002; 52(10):745-53. PubMed ID: 12442637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1.
    Shirasaka Y; Suzuki K; Shichiri M; Nakanishi T; Tamai I
    Drug Metab Pharmacokinet; 2011; 26(2):171-9. PubMed ID: 21206133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
    Vavricka SR; Van Montfoort J; Ha HR; Meier PJ; Fattinger K
    Hepatology; 2002 Jul; 36(1):164-72. PubMed ID: 12085361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.
    Nakai D; Nakagomi R; Furuta Y; Tokui T; Abe T; Ikeda T; Nishimura K
    J Pharmacol Exp Ther; 2001 Jun; 297(3):861-7. PubMed ID: 11356905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.
    Tokui T; Nakai D; Nakagomi R; Yawo H; Abe T; Sugiyama Y
    Pharm Res; 1999 Jun; 16(6):904-8. PubMed ID: 10397612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new acyl-CoA cholesterol acyltransferase inhibitor SMP-797 does not interact with statins via OATP1B1 in human cryopreserved hepatocytes and oocytes expressing systems.
    Kitamura A; Imai S; Yabuki M; Komuro S
    Biopharm Drug Dispos; 2007 Dec; 28(9):517-25. PubMed ID: 17918775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitavastatin - pharmacological profile from early phase studies.
    Catapano AL
    Atheroscler Suppl; 2010 Dec; 11(3):3-7. PubMed ID: 21193152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys.
    Takahashi T; Ohtsuka T; Yoshikawa T; Tatekawa I; Uno Y; Utoh M; Yamazaki H; Kume T
    Drug Metab Dispos; 2013 Oct; 41(10):1875-82. PubMed ID: 23929936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin.
    Lee HI; Choi CI; Sa JH; Lee YJ; Bae JW; Jang CG; Lee SY
    Int J Clin Pharmacol Ther; 2014 Nov; 52(11):981-5. PubMed ID: 25138679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
    Kajinami K; Takekoshi N; Saito Y
    Cardiovasc Drug Rev; 2003; 21(3):199-215. PubMed ID: 12931254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between several medicines and statins.
    Fujino H; Saito T; Tsunenari Y; Kojima J
    Arzneimittelforschung; 2003; 53(3):145-53. PubMed ID: 12705168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.
    Wen J; Xiong Y
    J Clin Pharm Ther; 2010 Feb; 35(1):99-104. PubMed ID: 20175818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pitavastatin: an overview.
    Saito Y
    Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.